| Title: |
Effectiveness of the Traditional Japanese Medicine Goshajinkigan in Preventing Paclitaxel-Induced Peripheral Neuropathy: A Multicenter Randomized Comparative Trial |
| Authors: |
Matsumura, Yukiko; Futagami, Masayuki; Baba, Tsukasa; Soeda, Shu; Watari, Hidemichi; Terada, Yukihiro; Tokunaga, Hideki; Nagase, Satoru; Nakanishi, Toru; Kaiho, Michiko; Yokoyama, Yoshihito |
| Contributors: |
Japan Society for the Promotion of Science |
| Source: |
Integrative Cancer Therapies ; volume 23 ; ISSN 1534-7354 1552-695X |
| Publisher Information: |
SAGE Publications |
| Publication Year: |
2024 |
| Description: |
Objective: Development of chemotherapy-induced peripheral neuropathy (CIPN) poses significant challenges in cancer treatment, often leading to dose reductions or treatment discontinuation. Goshajinkigan (GJG), a traditional Japanese medicine, has shown promise for alleviating CIPN symptoms. This multicenter, randomized controlled trial aimed to prospectively examine the efficacy of GJG in preventing paclitaxel-induced peripheral neuropathy. Methods: This study enrolled 55 patients with ovarian cancer undergoing first-line chemotherapy using paclitaxel and carboplatin. The participants were randomized into Groups A (GJG initiation after onset of grade 2 neuropathy) and B (prophylactic administration of GJG from 1 week before chemotherapy). The primary endpoints were the proportion with a maximum sensory neuropathy grade and visual analog scale (VAS) scores. The secondary endpoints were the rate of chemotherapy completion and paclitaxel dose reduction due to neurotoxicity. Results: Prophylactic GJG administration (Group B) resulted in significant benefits. While both groups had a similar incidence of grade 2 sensory neuropathy, all patients in Group B with grade 2 neuropathy completed treatment without requiring additional analgesics. Group B exhibited lower VAS scores by the end of the study, reduced reliance on adjuvant analgesics (27.3% vs 66.7% in Group A), and significantly less frequent persistent CIPN 6 months post-chemotherapy (18.2% vs 55.6% in Group A). No differences were observed in the chemotherapy completion rates or CIPN-related changes between the groups. Conclusion: GJG, when administered prophylactically, showed potential for mitigating CIPN symptoms during paclitaxel chemotherapy. While promising, further research with placebo controls and objective measures is essential to comprehensively validate these findings. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1177/15347354241278635 |
| Availability: |
https://doi.org/10.1177/15347354241278635; https://journals.sagepub.com/doi/pdf/10.1177/15347354241278635; https://journals.sagepub.com/doi/full-xml/10.1177/15347354241278635 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.9F50F71C |
| Database: |
BASE |